Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70725 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Samantha Avila und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Kaiser Permanente Oakland Medical Center, Oakland, California, USA. Hauptthemen laut MEDLINE: Schizophrenia, Benzilates, Nortropanes, Antipsychotic Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Xanomeline‐trospium chloride (Cobenfy, formerly KarXT) is a first‐in‐class, oral central M1/M4 muscarinic receptor agonist approved for the treatment of schizophrenia in adults. Cobenfy represents a paradigm shift by avoiding direct dopamine D2 receptor blockade and thus significantly reduces the burden of metabolic, extrapyramidal, and sedative side effects observed in standard first and second‐generation antipsychotics. Trospium chloride is a peripheral muscarinic antagonist with negligible blood–brain barrier penetration. Cobenfy is co‐formulated with trospium to minimize peripheral cholinergic effects caused by xanomeline. Under fasting conditions, xanomeline and trospium reach peak plasma concentrations ( T max ) in 2 and 1 h, and maximum concentrations ( C max ) of 1955 and 5787 pg/mL, respectively. While food intake does not change xanomeline pharmacokinetics, it reduces trospium C max by around 70%. Xanomeline has a high volume of distribution (10,800 L) and is metabolized by several cytochrome P450 (CYP) enzymes. Trospium is a P‐glycoprotein (P‐gp) substrate and is 85% eliminated in feces. In phase III clinical trials (EMERGENT‐2, EMERGENT‐3), Cobenfy significantly reduced PANSS total scores (least squares mean difference −9.6 and −8.4, respectively; p < 0.0001) compared to placebo. Treatment‐emergent adverse events were primarily mild to moderate in severity and were mainly transient nausea (19%), constipation (17%), dyspepsia (15%), and vomiting (14%). Discontinuation rates due to adverse events were low (6.2% vs. 5.2% for placebo), and Cobenfy was not associated with weight gain, extrapyramidal symptoms, or cardiometabolic risks seen in conventional antipsychotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.
- The Permanente Medical Group, Oakland, Northern California, USA.
ORCID-Profile: Ingrid L Chen
Zitieren
APA
Avila, S., & Chen, I. L. (2026). Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science. https://doi.org/10.1111/cts.70725
Vancouver
Avila S, Chen IL. Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science. 2026. doi:10.1111/cts.70725
BibTeX
@article{Avila2026,
author = {Avila, Samantha and Chen, Ingrid L},
title = {Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70725}
}
EUVIMED